Hospira earnings up 95%; NICE restricts Bristol-Myers' hep C combo;

@FiercePharma: Report: 'Precision farming' set to revolutionize livestock care. FierceAnimalHealth story | Follow @FiercePharma

@EricPFierce: As Hospira expands recall of Ketorolac to 37M vials you've got to wonder what Pfizer thinks. FiercePharmaManufacturing article | Follow @EricPFierce

@CarlyHFierce: With new cash on its way, it's back to buying for deal-happy Allergan, CEO says. Story | Follow @CarlyHFierce

> Hospira ($HSP) reported Q2 earnings per share up 95% in what may be its last report as a public company before being consumed in a $17 billion deal by Pfizer ($PFE). Release

> Critics say the second attempt by England's National Institute for Health and Care Excellence (NICE) to draft guidance for Type 2 diabetes drug treatments is still flawed. Report

> England's price watchdog NICE in new guidance says Bristol-Myers Squibb's ($BMY) hep C combo Daklinza will not be offered for patients with genotype 3, which BMS says accounts for 45% of all cases in the country. Story

> The Saskatchewan government has added AbbVie's ($ABBV) Holkira Pak to its coverage after already adding Sovaldi and Harvoni. Report

Medical Device News

@FierceMedDev: ICYMI: Cepheid readies for 2016 launch of point-of-care molecular Dx system for use anywhere. Article | Follow @FierceMedDev

@EmilyWFierce: Bangalore-based startup using silk to make cheap, disposable diagnostic tests. Wired article | Follow @EmilyWFierce

> FDA approves first weight-loss balloon, giving the obese a minimally invasive option. Story

> GE Healthcare to spend $1B+ in training 2 million global healthcare workers by 2020. More

> Startup raises $35M to back first FDA-approved dermal filler for acne scars. Article

Biotech News

@FierceBiotech: ICYMI yesterday: Patrick Soon-Shiong: NantKwest is starting down the path to conquering cancer. Article | Follow @FierceBiotech

@JohnCFierce: I'm putting together a half-day biotech conference in London October 12, at the Royal Society of Medicine. Should be fun. | Follow @JohnCFierce

@DamianFierce: $GILD has ~$14.7 billion~ in cash and equivalents right now. | Follow @DamianFierce

> Foresite Capital reloads with a $450M biotech venture fund. More

> Boehringer bets up to $730M on a new lung cancer drug. Story

> Sanofi's diabetes combo clears a clinical hurdle in a race with Novo Nordisk. Article

Biotech Research News

> CSHL researchers report promising mouse study for Rett syndrome. Item

> NIH successfully completes animal studies for new MERS vaccine. Report

> Blocking cell-to-cell communication shows efficacy in mouse model of glioblastoma. More

> Mass General team develops a gene therapy for recurrent ovarian cancer. Article

> CRISPR/Cas9 project discovers a better method to edit T cells. Story

Diagnostics News

> Johns Hopkins researchers unveil low-cost smartphone test for chlamydia. Report

> Castle Biosciences reels in $11M for cancer Dx. News

> Valeant to acquire IBSchek to complement its irritable bowel syndrome med. Article

> Bio-Rad Labs grabs FDA approval for next-gen HIV test. Item

> R-Biopharm to develop companion diagnostic for Apogenix's cancer candidate. Story

Pharma Marketing News

> Sanofi's LixiLan hits PhIII goal, moving one step closer to a Novo showdown. Report

> Last blast? New Amgen TV ad spotlights Neulasta delivery just months before patent expiration. More

> To hardest-to-treat patients, Sanofi's Praluent looks cheap. Item

> Merck-owned Physicians Interactive scoops up digital doc community to bolster services. Story

> Brand-building Abbott runs up marathon sponsorship total. Article

And Finally... Drug overdoses have risen 400% since 1999 up to 145,000, CDC reports, reaching epidemic levels as doctors overprescribe pain meds that then get abused. Report

Suggested Articles

Download our solutions overview to discover how CoverMyMeds can make a difference for your brand.

In a bladder cancer field chock-full of checkpoint inhibitors, Pfizer and Merck KGaA’s Bavencio has a chance to get ahead thanks to new data.

The FDA backtracked on its earlier testing and found NDMA contamination in the extended release formulation of certain generic versions of metformin.